Loading...
Several new adjunctive therapies for coronary artery disease (CAD) were investigated or approved in 2018. The FDA recently approved a new 2.5-mg dose of rivaroxaban (Xarelto) based largely on a trial of 27,000 patients with symptomatic or revascularized CAD or symptomatic peripheral artery disease. CAD patients younger than 65 were required to have atherosclerosis in a second vascular bed or at least two high-risk factors. Exclusion criteria included high risk for bleeding, serious comorbidities, glomerular filtration rate <15 mL/minute, severe heart failure, and need for dual antiplatelet therapy. Patients were randomized to rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily), rivaroxaban alone (5 mg twice daily), or aspirin alone…